Cargando…
Usefulness of [(11)C] Methionine PET in the Differentiation of Tumefactive Multiple Sclerosis from High Grade Astrocytoma
Tumefactive multiple sclerosis (tumefactive MS) is an atypical variant of MS characterized by a large isolated demyelinating lesion. Because tumefactive MS mimics high grade astrocytoma clinically and radiologically, it is difficult to distinguish between the two using only traditional diagnostic mo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Neurosurgical Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527963/ https://www.ncbi.nlm.nih.gov/pubmed/30996153 http://dx.doi.org/10.2176/nmc.oa.2018-0287 |
_version_ | 1783420121231917056 |
---|---|
author | HASHIMOTO, Satoka INAJI, Motoki NARIAI, Tadashi KOBAYASHI, Daisuke SANJO, Nobuo YOKOTA, Takanori ISHII, Kenji TAKETOSHI, Maehara |
author_facet | HASHIMOTO, Satoka INAJI, Motoki NARIAI, Tadashi KOBAYASHI, Daisuke SANJO, Nobuo YOKOTA, Takanori ISHII, Kenji TAKETOSHI, Maehara |
author_sort | HASHIMOTO, Satoka |
collection | PubMed |
description | Tumefactive multiple sclerosis (tumefactive MS) is an atypical variant of MS characterized by a large isolated demyelinating lesion. Because tumefactive MS mimics high grade astrocytoma clinically and radiologically, it is difficult to distinguish between the two using only traditional diagnostic modalities, such as routine magnetic resonance imaging. [(11)C] methionine positron emission tomography (MET PET) has been known as a useful diagnostic tool for glioma. However, it has not been established as a diagnostic tool for tumefactive MS yet. Therefore, the objective of this study was to evaluate the performance of MET PET in differentiating tumefactive MS from high grade astrocytoma. We studied patients with tumefactive MS [six patients (three men, three women), 7 lesions] and 77 patients with astrocytoma (World Health Organization grade II: 13 patients, grade III: 28 patients, and grade IV: 36 patients), and we compared MET uptake of tumefactive demyelinating lesions and astrocytoma. For MET PET analysis, Lesion/Normal region ratios (L/N ratios) were calculated and compared between tumefactive demyelinating lesions and astrocytoma. On MET PET, the L mean/N ratio of tumefactive MS was 1.18 ± 0.50, which was significantly lower than that of high-grade glioma (astrocytoma grade III: 1.95 ± 0.62, P = 0.006; grade IV: 2.35 ± 0.54, P <0.0001). The L maximum (L max)/N ratio of tumefactive demyelinating lesion was also significantly lower than that of high grade astrocytoma (tumefactive MS: 1.89 ± 0.55; astrocytoma grade III: 3.37 ± 1.36, P = 0.0232; astrocytoma grade IV: 4.35 ± 1.30, P <0.0001). In conclusion, MET PET can help differentiate tumefactive MS from high grade astrocytoma. |
format | Online Article Text |
id | pubmed-6527963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Japan Neurosurgical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65279632019-05-21 Usefulness of [(11)C] Methionine PET in the Differentiation of Tumefactive Multiple Sclerosis from High Grade Astrocytoma HASHIMOTO, Satoka INAJI, Motoki NARIAI, Tadashi KOBAYASHI, Daisuke SANJO, Nobuo YOKOTA, Takanori ISHII, Kenji TAKETOSHI, Maehara Neurol Med Chir (Tokyo) Original Article Tumefactive multiple sclerosis (tumefactive MS) is an atypical variant of MS characterized by a large isolated demyelinating lesion. Because tumefactive MS mimics high grade astrocytoma clinically and radiologically, it is difficult to distinguish between the two using only traditional diagnostic modalities, such as routine magnetic resonance imaging. [(11)C] methionine positron emission tomography (MET PET) has been known as a useful diagnostic tool for glioma. However, it has not been established as a diagnostic tool for tumefactive MS yet. Therefore, the objective of this study was to evaluate the performance of MET PET in differentiating tumefactive MS from high grade astrocytoma. We studied patients with tumefactive MS [six patients (three men, three women), 7 lesions] and 77 patients with astrocytoma (World Health Organization grade II: 13 patients, grade III: 28 patients, and grade IV: 36 patients), and we compared MET uptake of tumefactive demyelinating lesions and astrocytoma. For MET PET analysis, Lesion/Normal region ratios (L/N ratios) were calculated and compared between tumefactive demyelinating lesions and astrocytoma. On MET PET, the L mean/N ratio of tumefactive MS was 1.18 ± 0.50, which was significantly lower than that of high-grade glioma (astrocytoma grade III: 1.95 ± 0.62, P = 0.006; grade IV: 2.35 ± 0.54, P <0.0001). The L maximum (L max)/N ratio of tumefactive demyelinating lesion was also significantly lower than that of high grade astrocytoma (tumefactive MS: 1.89 ± 0.55; astrocytoma grade III: 3.37 ± 1.36, P = 0.0232; astrocytoma grade IV: 4.35 ± 1.30, P <0.0001). In conclusion, MET PET can help differentiate tumefactive MS from high grade astrocytoma. The Japan Neurosurgical Society 2019-05 2019-04-17 /pmc/articles/PMC6527963/ /pubmed/30996153 http://dx.doi.org/10.2176/nmc.oa.2018-0287 Text en © 2019 The Japan Neurosurgical Society This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Original Article HASHIMOTO, Satoka INAJI, Motoki NARIAI, Tadashi KOBAYASHI, Daisuke SANJO, Nobuo YOKOTA, Takanori ISHII, Kenji TAKETOSHI, Maehara Usefulness of [(11)C] Methionine PET in the Differentiation of Tumefactive Multiple Sclerosis from High Grade Astrocytoma |
title | Usefulness of [(11)C] Methionine PET in the Differentiation of Tumefactive Multiple Sclerosis from High Grade Astrocytoma |
title_full | Usefulness of [(11)C] Methionine PET in the Differentiation of Tumefactive Multiple Sclerosis from High Grade Astrocytoma |
title_fullStr | Usefulness of [(11)C] Methionine PET in the Differentiation of Tumefactive Multiple Sclerosis from High Grade Astrocytoma |
title_full_unstemmed | Usefulness of [(11)C] Methionine PET in the Differentiation of Tumefactive Multiple Sclerosis from High Grade Astrocytoma |
title_short | Usefulness of [(11)C] Methionine PET in the Differentiation of Tumefactive Multiple Sclerosis from High Grade Astrocytoma |
title_sort | usefulness of [(11)c] methionine pet in the differentiation of tumefactive multiple sclerosis from high grade astrocytoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527963/ https://www.ncbi.nlm.nih.gov/pubmed/30996153 http://dx.doi.org/10.2176/nmc.oa.2018-0287 |
work_keys_str_mv | AT hashimotosatoka usefulnessof11cmethioninepetinthedifferentiationoftumefactivemultiplesclerosisfromhighgradeastrocytoma AT inajimotoki usefulnessof11cmethioninepetinthedifferentiationoftumefactivemultiplesclerosisfromhighgradeastrocytoma AT nariaitadashi usefulnessof11cmethioninepetinthedifferentiationoftumefactivemultiplesclerosisfromhighgradeastrocytoma AT kobayashidaisuke usefulnessof11cmethioninepetinthedifferentiationoftumefactivemultiplesclerosisfromhighgradeastrocytoma AT sanjonobuo usefulnessof11cmethioninepetinthedifferentiationoftumefactivemultiplesclerosisfromhighgradeastrocytoma AT yokotatakanori usefulnessof11cmethioninepetinthedifferentiationoftumefactivemultiplesclerosisfromhighgradeastrocytoma AT ishiikenji usefulnessof11cmethioninepetinthedifferentiationoftumefactivemultiplesclerosisfromhighgradeastrocytoma AT taketoshimaehara usefulnessof11cmethioninepetinthedifferentiationoftumefactivemultiplesclerosisfromhighgradeastrocytoma |